CRO

Charles River amps up its biologics testing

Charles River Laboratories ($CRL) is kicking off an all-encompassing service that will allow its biotech and pharma clients to hand over their quality-control testing for biologics en masse, a method the preclinical CRO says can save time and money. Under a platform dubbed RightSource, Charles River and its clients will first determine the ideal split between in- and outsourcing, and then the CRO will take over, managing QC testing through its own labs, its sponsors' facilities and some external vendors. That flexible yet centralized approach will make for speedy, cost-effective biologics and biosimilars testing, according to Charles River. More